Levodopa
- Generic Name
- Levodopa
- Brand Names
- Dhivy, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Sinemet, Stalevo
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO4
- CAS Number
- 59-92-7
- Unique Ingredient Identifier
- 46627O600J
- Background
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the b...
- Indication
Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-enceph...
- Associated Conditions
- Paralysis agitans, Parkinson's Disease (PD), Parkinsonism, Parkinsonism post encephalitic, Restless Legs Syndrome (RLS), Advanced Motor fluctuations
- Associated Therapies
- -
Measuring Parkinson's Disease Progression
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Kevin J. Black, MD
- Target Recruit Count
- 31
- Registration Number
- NCT03205956
- Locations
- 🇺🇸
Washington University School of Medicine, Movement Disorders Center, Saint Louis, Missouri, United States
Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 50
- Registration Number
- NCT03119636
- Locations
- 🇨🇳
The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China
Dose-finding Pharmacokinetic Study in Healthy Males
- First Posted Date
- 2017-02-16
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 56
- Registration Number
- NCT03055936
- Locations
- 🇩🇪
Nuvisan Pharma Services, Neu-Ulm, Germany
A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 29
- Registration Number
- NCT03000569
- Locations
- 🇺🇸
Sage Investigational Site, Orem, Utah, United States
Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02769793
- Locations
- 🇰🇷
SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study of L-DOPA for Depression and Slowing in Older Adults
- Conditions
- Interventions
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 47
- Registration Number
- NCT02744391
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- CleveXel Pharma
- Target Recruit Count
- 21
- Registration Number
- NCT02641054
- Locations
- 🇫🇷
Clevexel Pharma, Maisons-Alfort, France
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 67
- Registration Number
- NCT02601586
- Locations
- 🇫🇷
University Hospital of Bordeaux, Bordeaux, France
🇫🇷CHU Amiens, Amiens, France
🇫🇷Henri Mondor Hospital, Créteil, France
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia
- Conditions
- Interventions
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT02578849
- Locations
- 🇩🇰
Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus C, Denmark
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 103
- Registration Number
- NCT02560389
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.